Apolipoprotein e mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 8, 2011, Pages 1834-1841

  Rosales, Corina ^a   Tang, Daming ^a   Gillard, Baiba K ^a   Courtney, Harry S ^b   Pownall, Henry J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

atherosclerosis; lipids; lipoproteins; pharmacokinetics

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN E; APOLIPOPROTEIN I; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; RECOMBINANT PROTEIN; RECOMBINANT STREPTOCOCCAL SERUM OPACITY FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; IN VIVO STUDY; LIVER CLEARANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BACTERIAL PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIDE HYDROLASES; RECEPTORS, LDL; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 80051552226     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.224360     Document Type: Article

References (40)

1. Courtney HS, Pownall HJ. The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets highdensity lipoproteins. J Biomed Biotechnol. 2010:956071.
2. Courtney HS, Li Y, Twal WO, Argraves WS. Serum opacity factor is a streptococcal receptor for the extracellular matrix protein fibulin-1. J Biol Chem. 2009;284:12966-12971.
3. Courtney HS, Zhang YM, Frank MW, Rock CO. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J Biol Chem. 2006;281: 5515-5521. (Pubitemid 43847646)
4. Courtney HS, Hasty DL, Li Y, Chiang HC, Thacker JL, Dale JB. Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of m type 2 Streptococcus pyogenes. Mol Microbiol. 1999; 32:89-98. (Pubitemid 29164136)
5. Courtney HS, Dale JB, Hasty DL. Mapping the fibrinogen-binding domain of serum opacity factor of group a streptococci. Curr Microbiol. 2002;44:236-240. (Pubitemid 36929642)
6. Oehmcke S, Podbielski A, Kreikemeyer B. Function of the fibronectinbinding serum opacity factor of Streptococcus pyogenes in adherence to epithelial cells. Infect Immun. 2004;72:4302-4308. (Pubitemid 38821950)
7. Gillard BK, Courtney HS, Massey JB, Pownall HJ. Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. Biochemistry. 2007;46: 12968-12978. (Pubitemid 350086217)
8. Gillard BK, Rosales C, Pillai BK, Lin HY, Courtney HS, Pownall HJ. Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol. Biochemistry. 2010;49:9866-9873.
9. Han M, Gillard BK, Courtney HS, Ward K, Rosales C, Khant H, Ludtke SJ, Pownall HJ. Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. Biochemistry. 2009;48:1481-1487.
10. Tchoua U, Rosales C, Tang D, Gillard BK, Vaughan A, Lin HY, Courtney HS, Pownall HJ. Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects. Lipids. 2010;45:1117-1126.
11. Ponsin G, Pulcini T, Sparrow JT, Gotto AM Jr, Pownall HJ. High density lipoprotein interconversions in rat and man as assessed with a novel nontransferable apolipopeptide. J Biol Chem. 1993;268:3114-3119. (Pubitemid 23070933)
12. Rosales C, Gillard BK, Courtney HS, Blanco-Vaca F, Pownall HJ. Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. Biochemistry. 2009;48: 8070-8076.
13. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMPinducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508-34511.
14. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
15. Liang HQ, Rye KA, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin:cholesterol acyltransferase. J Lipid Res. 1996;37: 1962-1970.
16. Gillard BK, Lin HY, Massey JB, Pownall HJ. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta. 2009; 1791:1125-1132.
17. Lee JY, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, Thomas MJ, Parks JS. Prebeta high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res. 2004;45:716-728. (Pubitemid 38405678)
18. Webb NR, de Beer MC, Asztalos BF, Whitaker N, van der Westhuyzen DR, de Beer FC. Remodeling of HDL remnants generated by scavenger receptor class B type I. J Lipid Res. 2004;45:1666-1673. (Pubitemid 39296206)
19. Hime NJ, Drew KJ, Wee K, Barter PJ, Rye KA. Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. J Lipid Res. 2006;47:115-122. (Pubitemid 43107455)
20. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein. Adenovirusmediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem. 1997;272:27393-27400. (Pubitemid 27452707)
21. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16. (Pubitemid 29022581)
22. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119:3236-3245.
23. Kashyap VS, Santamarina-Fojo S, Brown DR, Parrott CL, Applebaum-Bowden D, Meyn S, Talley G, Paigen B, Maeda N, Brewer HB Jr. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest. 1995;96: 1612-1620.
24. Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, Nakamuta M, Chan L. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem. 1996;271: 6852-6860. (Pubitemid 26104786)
25. Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH. Anthrax fusion protein therapy of cancer. Curr Protein Pept Sci. 2002; 3:399-407. (Pubitemid 34778183)
26. de Maio M. Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther. 2008;8:791-798. (Pubitemid 351860208)
27. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007;34:318-327. (Pubitemid 350057575)
28. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
29. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414-417. (Pubitemid 27227207)
30. Wang N, Arai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein apoB, low density lipoprotein apoB, and high density lipoprotein in transgenic mice. J Biol Chem. 1998;273:32920-32926. (Pubitemid 28557684)
31. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem. 1999;274:7165-7171.
32. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, Tall AR. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem. 1999;274:33398-33402. (Pubitemid 129511644)
33. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci USA. 1998;95:10194-10199. (Pubitemid 28415317)
34. Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem. 1999;274: 2366-2371.
35. Ueda Y, Gong E, Royer L, Cooper PN, Francone OL, Rubin EM. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem. 2000;275: 20368-20373. (Pubitemid 30457612)
36. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000;20:721-727. (Pubitemid 30151687)
37. Varban ML, Rinninger F, Wang N, Fairchild-Huntress V, Dunmore JH, Fang Q, Gosselin ML, Dixon KL, Deeds JD, Acton SL, Tall AR, Huszar D. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci USA. 1998;95:4619-4624. (Pubitemid 28207962)
38. Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild-Huntress V, Donovan MJ, Tall AR. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. Arterioscler Thromb Vasc Biol. 2000;20:1068-1073. (Pubitemid 30207584)
39. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
40. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113:2548-2555. (Pubitemid 43948034)